|Drug class||Gadolinium complex|
|Main uses||MRI contrast agent used to detect abnormal blood vessels|
|Side effects||Pain at the site of injection, headache, nausea, dizziness|
|Typical dose||0.1 mL/kg|
|Chemical and physical data|
|Molar mass||970.10 g·mol−1|
|3D model (JSmol)|
Gadopiclenol, sold under the brand name Elucirem, is a contrast agent used in magnetic resonance imaging (MRI) to detect lesions with abnormal blood vessels. It may be used in those who are at least two years old. It is given by injection into a vein.
Common side effects include pain at the site of injection, headache, nausea, and dizziness. Other side effects may include nephrogenic systemic fibrosis, allergic reactions, and retention of gadolinium. Safety in pregnancy is unclear. It is a paramagnetic macrocyclic non-ionic complex of gadolinium.
It is generally given at a dose of 0.1 mL/kg.
- "Elucirem- gadopiclenol injection". DailyMed. 12 October 2022. Archived from the original on 16 October 2022. Retrieved 16 October 2022.
- "Drug Approval Package: Elucirem". U.S. Food and Drug Administration (FDA). 20 October 2022. Archived from the original on 4 December 2022. Retrieved 4 December 2022.
- "FDA Approves Gadopiclenol for Contrast-Enhanced Magnetic Resonance Imaging". Pharmacy Times. Archived from the original on 27 September 2022. Retrieved 16 December 2022.
- World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 80". WHO Drug Information. 32 (3). hdl:10665/330907.
- Clinical trial number NCT03996447 for "Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) (PICTURE)" at ClinicalTrials.gov
- Clinical trial number NCT03986138 for "Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI) (PROMISE)" at ClinicalTrials.gov